180
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

VISTA-Ig ameliorates OXA-induced allergic dermatitis symptoms in mice

, , , &
Pages 380-385 | Received 10 Jan 2021, Accepted 24 Apr 2021, Published online: 24 May 2021

References

  • Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
  • Veiga SP. Epidemiology of atopic dermatitis: A review. Allergy Asthma Proc. 2012;33:227–234.
  • Sabat R, Wolk K, Loyal L, et al. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359–377.
  • Remitz A, De Pità O, Mota A, et al. Position statement: topical calcineurin inhibitors in atopic dermatitis. J Eur Acad Dermatol Venereol. 2018;32(12):2074–2082.
  • Hernández-Martín A, Noguera-Morel L, Bernardino-Cuesta B, et al. Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients. J Eur Acad Dermatol Venereol. 2017;31(5):837–842.
  • Prussick L, Plotnikova N, Gottlieb A. Mycophenolate Mofetil in Severe Atopic Dermatitis: A Review. J Drugs Dermatol. 2016;15(6):715–718.
  • Anderson K, Putterman E, Rogers RS, et al. Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review. Pediatr Dermatol. 2019;36(3):298–302.
  • Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Lett. 2017;22(6):1–4.
  • Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121–1130.
  • Nagai S, Azuma M. The CD28-B7 Family of Co-signaling Molecules. Adv Exp Med Biol. 2019;1189:25–51.
  • Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory functions of VISTA. Immunol Rev. 2017;276(1):66–79.
  • Wang L, Rubinstein R, Lines JL, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. Exp Med. 2011;208(3):577–592.
  • Flies DB, Han X, Higuchi T, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. J Clin Invest. 2014;124(5):1966–1975.
  • Prodeus A, Abdul-Wahid A, Sparkes A, et al. VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses. JCI Insight. 2017;2(18):e94308.
  • Kawakami T, Ando T, Kimura M, et al. Mast cells in atopic dermatitis. Curr Opin Immunol. 2009;21(6):666–678.
  • Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23(1):515–548.
  • Wang G, Hu P, Yang J, et al. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int. 2011;31(4):513–519.
  • Uo L, Zhu G, Xu H, et al. B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets. PLoS One. 2015;10(6):e0130126.
  • Lee IF, Wang X, Hao J, et al. B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice. Cell Immunol. 2013;282(1):1–8.
  • Wang L, Le Mercier I, Putra J, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci U S A. 2014;111(41):14846–14851.
  • Mulati K, Hamanishi J, Matsumura N, et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 2019;120(1):115–127.
  • Ohno T, Zhang C, Kondo Y, et al. The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses. Int Immunol. 2018;30(1):3–11.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.